NanoViricides Signs Agreement with the University of Wisconsin for Testing of Anti-Viral Candidates

NanoViricides, Inc. (NYSEMKT:NNVC) entered into an agreement with the University of Wisconsin for the evaluation of its nanoviricides® drug candidates in models of ocular herpes virus infections.
According to the press release:

The studies will be performed in the laboratory of Dr. Curtis Brandt, an expert in herpes simplex virus infections and in evaluating anti-viral agents. The Company has previously reported the successes of its nanoviricides drug candidates in pre-clinical studies of dermal herpes virus infections in mouse models.  The studies in Dr. Brandt’s laboratory will be critical in optimizing its anti-herpes drug candidates against ocular herpes virus infections. The goal of these studies will be to identify a drug development candidate as a treatment for ocular keratitis in humans caused by herpes simplex virus infections.

Dr.Eugene Seymour, MD, MPH, CEO of the Company, commented:

We are progressing rapidly in developing drug candidates against different herpesvirus infections and related indications. Dr. Brandt’s expertise and this agreement with CORL at the University of Wisconsin will help us identify a clinical drug candidate against herpes keratitis (HK) in a relatively short time frame.

 Click here to view the full press release.